selenium yeast supplementation

Phase 2Small molecule

FFirst Affiliated Hospital of Chongqing Medical University

selenium yeast supplementation is one of 4 small molecule programs targeting Depression - Major Depressive Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Depression - Major Depressive DisorderRecruiting

Depression - Major Depressive DisorderPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Depression - Major Depressive Disorder

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Approved

1 2

Mirapex

Lexapro

1 4

selenium yeast supplementation

FFirst Affiliated Hospital of Chongqing Medical University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Depression - Major Depressive Disorder

NCT07203144

Clinical

Trials by Indication[1]

Depression - Major Depressive Disorder1 trial

Selenium Supplementation for Improving Depression in Children and Adolescents: Efficacy and Mechanistic Study

Recruiting·FFirst Affiliated Hospital of Chongqing Medical University·Phase 2·NCT07203144·172 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for selenium yeast supplementation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — selenium yeast supplementation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for selenium yeast supplementation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First Affiliated Hospital of Chongqing Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFirst Affiliated Hospital of Chongqing Medical University

selenium yeast supplementation

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Depression - Major Depressive Disorder1 trial

References

Drug Info

Quick Facts

Related News